Viatris (VTRS) Other Non-Current Liabilities (2019 - 2026)
Viatris' (VTRS) quarterly Other Non-Current Liabilities came in at $2.1 billion in Q1 2026, up 12.91% year-on-year from $1.8 billion in Q1 2025, and up 3.36% quarter-over-quarter from $2.0 billion in Q4 2025.
Viatris (VTRS) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Viatris' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $2.1 billion for Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 12.91% year-over-year to $2.1 billion in Q1 2026; TTM through Mar 2026 was $2.1 billion, a 12.91% increase from a year earlier, with the FY2025 full-year figure at $2.0 billion, up 3.9% from the prior year.
- Other Non-Current Liabilities climbed to $2.1 billion in Q1 2026 per VTRS's latest filing, from $2.0 billion in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $2.1 billion in Q1 2026 and bottomed at $345.0 million in Q1 2024.
- The 5-year median for Other Non-Current Liabilities is $1.8 billion (2022), against an average of $1.6 billion.
- Across the five-year window, Other Non-Current Liabilities slumped 79.94% in 2024 and surged 434.61% in 2025, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $1.8 billion in 2022, then declined by 13.64% to $1.5 billion in 2023, then grew by 27.84% to $1.9 billion in 2024, then increased by 3.9% to $2.0 billion in 2025, then increased by 3.36% to $2.1 billion in 2026.
- Per Business Quant, the three latest VTRS Other Non-Current Liabilities figures stand at $2.1 billion (Q1 2026), $2.0 billion (Q4 2025), and $1.8 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.08 Bn |
| Dec 31, 2025 | 2.01 Bn |
| Sep 30, 2025 | 1.82 Bn |
| Jun 30, 2025 | 1.84 Bn |
| Mar 31, 2025 | 1.84 Bn |
| Dec 31, 2024 | 1.94 Bn |
| Sep 30, 2024 | 1.87 Bn |
| Jun 30, 2024 | 345.00 Mn |
| Mar 31, 2024 | 345.00 Mn |
| Dec 31, 2023 | 1.52 Bn |
| Sep 30, 2023 | 1.65 Bn |
| Jun 30, 2023 | 1.67 Bn |
| Mar 31, 2023 | 1.72 Bn |
| Dec 31, 2022 | 1.76 Bn |
| Sep 30, 2022 | 1.75 Bn |
| Jun 30, 2022 | 1.81 Bn |
| Mar 31, 2022 | 1.88 Bn |
| Dec 31, 2021 | 1.93 Bn |
| Sep 30, 2021 | 2.05 Bn |
| Jun 30, 2021 | 2.24 Bn |